SBRT 2016

Evidence of combining SBRT & targeted drugs

Agent

Patients

Studies

Primary Tumor

SRT Location

Antibodies Bevacizumab Cetuximab Trastuzumab Ipilimumab Nivolumab TKIs Sorafenib Sunitinib Gefitinib Erlotinib Crizitonib Vemurafenib Dabrafenib Trametinib

202 251

11

Glioma, NSCLC, CRC

Brain

6 1 8 2 3 2 3 1 2 6 4 1

SCCHNC Mamma

Head-and-neck

7

Brain

Melanoma, Adenocarcinoma Lung

121

Brain, Liver

27

Melanoma

Brain

142

RCC, HCC, CRC

Brain, Spine, Abdomen

RCC, Lung, Breast, Melanoma,

Brain, Abdomen

15 47 24 39 75 56

NSCLC, Glioma

Brain, Lung

NSCLC NSCLC

Abdomen, Lung, Bone

Brain, Lung, Abdomen, Bone

Melanoma Melanoma Melanoma

Brain, Spine

Brain Brain

6

• Very little data available: 1042 patients in 50 studies

/ ESTRO SBRT COURSE 2016 - Matthias Guckenberger

21